Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Photoluminescence: Applications01:14

Photoluminescence: Applications

410
Photoluminescence offers a wide range of applications due to its inherent sensitivity and selectivity. This technique allows for both direct and indirect analyses of the analyte. Direct quantitative analysis is possible when the analyte exhibits a favorable quantum yield for fluorescence or phosphorescence. However, an indirect analysis may be feasible if the analyte is not fluorescent or phosphorescent, or if the quantum yield is unfavorable. Indirect methods include reacting the analyte with...
410
Photoluminescence: Fluorescence and Phosphorescence01:23

Photoluminescence: Fluorescence and Phosphorescence

2.1K
Photoluminescence is a process where a molecule absorbs light energy and re-emits it in the form of light. This phenomenon occurs when a substance absorbs photons, promoting its electrons to higher energy level excited states, followed by a relaxation process in which the electrons return to their original ground state energy levels and emit light. Photoluminescence is widely observed in various materials, including semiconductors, and organic and inorganic compounds.
A pair of electrons in a...
2.1K
Blinding01:11

Blinding

2.5K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.5K
Variables Affecting Phosphorescence and Fluorescence01:26

Variables Affecting Phosphorescence and Fluorescence

509
Fluorescence and phosphorescence are essential phenomena in fields like analytical chemistry, biological imaging, and materials science, where they detect molecular properties and visualize cellular structures. Understanding the variables that influence these luminescent behaviors is crucial for maximizing accuracy and efficiency in their applications. These variables can broadly be grouped into chemical structure, solvent properties, and external conditions, each playing a distinct role in...
509
Pigmentation01:19

Pigmentation

2.5K
The color of the skin is influenced by a number of pigments, including melanin, carotene, and hemoglobin. Recall that melanin is produced by cells called melanocytes, which are found scattered throughout the stratum basale of the epidermis. The melanin is transferred to the keratinocytes via melanosomes.
Melanin occurs in two primary forms: eumelanin that provides black and brown pigment and pheomelanin that provides red color. Dark-skinned individuals produce more melanin than those with pale...
2.5K
Focusing of Light in the Eye01:16

Focusing of Light in the Eye

2.9K
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pain prevalence and intensity in advanced pancreatic cancer: a nationwide cohort study.

Pain·2026
Same author

Serum levels of the C-terminal pro-peptide of type V collagen have prognostic potential and are associated with a normal subtype of desmoplasia in a retrospective cohort of patients with esophagogastric cancer.

Therapeutic advances in medical oncology·2026
Same author

Antiphospholipid antibody formation during immune checkpoint inhibition in patients with cancer: a prospective cohort study.

Research and practice in thrombosis and haemostasis·2026
Same author

Circulating tumour DNA in oligometastatic oesophago-gastric cancers: applications, challenges, and future directions.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2026
Same author

Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study.

Therapeutic advances in medical oncology·2026
Same author

Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort study.

PloS one·2026
Same journal

Transplantation tolerance versus immune evasion: Mechanistic divergences and therapeutic frontiers for islet cell replacement.

Cell reports. Medicine·2026
Same journal

Differential T cell clonal dynamics underlie outcomes to frontline chemoimmunotherapy in advanced gastric cancer.

Cell reports. Medicine·2026
Same journal

Targeted DNA triplex-forming oligonucleotide liposome for pulmonary fibrosis gene therapy.

Cell reports. Medicine·2026
Same journal

Metabolomic and lifestyle profiles refine BMI-metabolic phenotypes in older adults.

Cell reports. Medicine·2026
Same journal

Targeting cytokine-like protein FAM3D alleviates atherosclerosis.

Cell reports. Medicine·2026
Same journal

High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.

Cell reports. Medicine·2026
See all related articles

Related Experiment Video

Updated: Jul 13, 2025

Author Spotlight: Advancing Optogenetics Research Using Lustro
03:26

Author Spotlight: Advancing Optogenetics Research Using Lustro

Published on: August 4, 2023

728

SPOTlight on GLOW.

Sarah Derks1, Hanneke W M van Laarhoven2

  • 1Amsterdam UMC location Free University, Medical Oncology, De Boelelaan 1118, Amsterdam, the Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.

Cell Reports. Medicine
|October 18, 2023
PubMed
Summary
This summary is machine-generated.

Zolbetuximab plus chemotherapy significantly improved outcomes for patients with Claudin-18.2-positive gastric cancer. This first-line treatment demonstrated superior efficacy compared to placebo and chemotherapy alone.

More Related Videos

Bioluminescent Optogenetics 2.0: Harnessing Bioluminescence to Activate Photosensory Proteins In Vitro and In Vivo
07:19

Bioluminescent Optogenetics 2.0: Harnessing Bioluminescence to Activate Photosensory Proteins In Vitro and In Vivo

Published on: August 4, 2021

4.7K
A Step Beyond BRET: Fluorescence by Unbound Excitation from Luminescence FUEL
07:04

A Step Beyond BRET: Fluorescence by Unbound Excitation from Luminescence FUEL

Published on: May 23, 2014

11.7K

Related Experiment Videos

Last Updated: Jul 13, 2025

Author Spotlight: Advancing Optogenetics Research Using Lustro
03:26

Author Spotlight: Advancing Optogenetics Research Using Lustro

Published on: August 4, 2023

728
Bioluminescent Optogenetics 2.0: Harnessing Bioluminescence to Activate Photosensory Proteins In Vitro and In Vivo
07:19

Bioluminescent Optogenetics 2.0: Harnessing Bioluminescence to Activate Photosensory Proteins In Vitro and In Vivo

Published on: August 4, 2021

4.7K
A Step Beyond BRET: Fluorescence by Unbound Excitation from Luminescence FUEL
07:04

A Step Beyond BRET: Fluorescence by Unbound Excitation from Luminescence FUEL

Published on: May 23, 2014

11.7K

Area of Science:

  • Oncology
  • Gastroenterology
  • Immunotherapy

Background:

  • Gastric and gastroesophageal junction adenocarcinomas represent a significant global health challenge.
  • Claudin-18.2 (CLDN18.2) is an emerging target in gastric cancer therapy.
  • Limited effective first-line treatment options exist for CLDN18.2-positive patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of zolbetuximab in combination with chemotherapy as a first-line treatment for CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.
  • To compare outcomes of zolbetuximab plus chemotherapy versus placebo plus chemotherapy.

Main Methods:

  • The GLOW trial was a randomized, double-blind, placebo-controlled, phase 3 study.
  • Patients received either zolbetuximab or placebo in combination with capecitabine and oxaliplatin.
  • Tumor CLDN18.2 expression and HER2 status were assessed.

Main Results:

  • Zolbetuximab combined with capecitabine and oxaliplatin demonstrated a statistically significant improvement in outcome compared to placebo and chemotherapy.
  • The treatment regimen was generally well-tolerated, with manageable side effects.
  • Specific efficacy endpoints, such as progression-free survival and overall survival, showed benefit.

Conclusions:

  • Zolbetuximab plus capecitabine and oxaliplatin is an effective first-line treatment option for patients with CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.
  • Targeting CLDN18.2 with zolbetuximab represents a promising advancement in gastric cancer therapy.
  • The GLOW trial provides high-level evidence supporting the use of zolbetuximab in this patient population.